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Recently within 2 days of each other, two of the leading medi-
cal journals published trials on the use of prehospital fresh frozen 
plasma (FFP) for trauma patients, reaching apparently different 
conclusions. In the New England Journal of Medicine article reporting 
om|_;u;_ovrb|-Ѵbu;7b1-ѴѴ-vl-Ő;uő|ub-Ѵķ"r;uu;|-Ѵ1 
found that two units of prehospital FFP was associated with an al-
lov|ƐƏѷvub-Ѵ-7-m|-];ĺm|_;om|uoѴo=-fouѴ;;7bm]=|;u
$u-l-$ub-ѴŐ$őu;rou|;7bm|_;-m1;|ķoou;;|-Ѵ2 found 
that the same volume of plasma had no survival advantage.
The concept of prehospital plasma is in theory attractive. You 
have an injured individual who is likely to need plasma in the next 
few hours, so why not preemptively reduce the bleeding by adminis-
|;ubm]rѴ-vl-=buv|ĵmblrou|-m|bvv;|o1omvb7;uķ_o;;uķbv|_-|
at the injury scene the patient is not likely to be deficient in clotting 
factors yet. The prehospital transfusion of blood products has been 
shown to improve survival in US military combat casualties injured 
bm=]_-mbv|-mĺ3
The normal range for clotting factors measured as percent of 
normal is approximately 50- 150 with a mean of 100. It follows, that 
the average individual can lose half their plasma volume and still 
have clotting factor levels in the normal range even after reconstitu-
|bomo=0Ѵoo7oѴl;ĺl-fouu;71|bombm1Ѵo||bm]=-1|ouv1-mo11u
in two relevant settings, firstly when there is marked hemodilution 
such as that following major fluid resuscitation and secondly due to 
consumption in the presence of disseminated intravascular coagula-
tion (DIC). With the exception of obstetric DIC at the time of deliv-
ery, this consumption is not usually so rapid to become a major issue 
in the prehospital management of trauma.
Fresh frozen plasma is obtained from whole blood donation or 
rѴ-vl-r_;u;vbvĺ)_bѴ; bm|_;$|ub-Ѵ |_;vr;1b=|_-||_;
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investigators do not specify the volume of the two units they 
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plasmapheresis, frozen within 24 hours and thawed rapidly in special 
equipment before administration. In a study one of us was involved 
in, measuring clotting factor levels before and after administration of 
four units of optimally thawed FFP just before infusion, the increase 
in clotting factor levels was 9%- 14%.4 Based on the volume of FFP 
bm=v;7 bm |_; ;u -m7 $ v|7b;vķ |_; bm1u;-v; bm =-1-
tor levels would be 7% at best. This suggests that if prehospital FFP 
provides benefit, it is unlikely that this is through the substitution of 
coagulation factors. Other modes of FFP benefit include protecting 
the endothelial glycocalyx and reducing vascular permeability and 
inflammation.5,6
);1olr-u;7|_;;u-m7$|ub-Ѵv Ѵoohbm] =ou7b=-
ferences in their design and conduct to shed light on the true ef-
fect of FFP, if any (Table 1). Of course, the simplest explanation for 
the difference in results could well be a combination of chance and 
Ѵoro;u=ou|_;$v|7ķ7;|oѴo;;m|u-|;-m7vl-ѴѴ
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fect meta- analysis approach would have been <10%, and the pooled 
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a significant benefit for plasma administration at both 24 hours 
(OR = 0.64, 95% CI 0.42- 0.98) and 1 month (OR = 0.67, 95% CI 0.46- 
0.98). Even under the more conservative random- effect approach, 
the visual inspection of the forest plot (Figure 1) would support both 
the hypothesis the two trials observing a different effect (as their 
effect sizes lie on opposite sides of the identity line) and instead 
representing random variation of the same effect (as the confidence 
intervals do overlap). However, there are clear differences between 
the trials, starting from the choice of results to report and the modal-
ity used to report them. The entry criteria for the two trials were the 
same in terms of blood pressure and heart rate measurements, but 
$_bvbv-mor;m-11;vv-u|b1Ѵ;m7;u|_;|;ulvo=|_;u;-|b;ollomv||ub0|bomŊomoll;u1b-ѴŊo	;ubvb1;mv;ķ_b1_r;ulb|vv;-m77bv|ub0|bombm
any medium, provided the original work is properly cited, the use is non- commercial and no modifications or adaptations are made.
šƑƏƐѶ$_;|_ouvĺResearch and Practice in Thrombosis and Haemostasis published by Wiley Periodicals, Inc on behalf of International Society on Thrombosis 
and Haemostasis.
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FFP Standard care FFP Saline
Patient characteristics
l0;u 230 271 65 60
];l;7b-mŐő 44 46 33 32.5
Male (%) 71.3 73.8 80 85
Blunt injury 81.3 83.4 46 53
uo|_uol0bm|bl;u-|boou!om
arrival at hospital
1.2 1.3 1.27 1.15
Injury severity
Prehospital intubation (%) 50 52 o|]b;m
Prehospital red cells (%) 26.1 42.1 o|]b;m
Transfused red cells in first 24 h (%) o|]b;m 55 58
Injury severity score (median) 22 21 27
Operations in first 24 h (%) 71.7 80.1 o|]b;m
Setting US air medical transport Denver, US ground transport
Median prehospital transfer time 
(min)
42 40 19 16
Entry qualification BP <90 mm Hg plus pulse >108 or BP <70 BP <90 mm Hg plus pulse >108 or BP <70
Randomization Cluster randomization to plasma or standard 
care at monthly intervals. Treating staff not 
blinded.
Individual randomization by the content of coolers. 
Treating staff not blinded
Intervention 2 units pre- thawed 
up to 5- day- old 
plasma
Standard care no fluid 
volume stipulated
2 units apheresis 
FFP approx 
ƔƏƏl
oul-Ѵv-Ѵbm;-vr;uv|-m7-u7
care (volume not same)
u;_ovrb|-Ѵ1uv|-ѴѴob7Őlő 500 900 150 250
Outcome
24- h mortality (%) 13.9 22.1 12 10
28- or 30- day mortality (%) 23.2 33 15 10
$ķom|uoѴo=-fouѴ;;7bm]=|;u$u-l-$ub-Ѵĸ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Study or subgroup Events Total Events Total Weight M-H, random, 95% CI M-H, random, 95% CI
Odds ratioPre-hospital FFP Standard of care Odds ratio
1.1.1 --- 24 h
COMBAT
PAMPer
Subtotal (95% CI)
Total events
Heterogeneity: τ = 0.13; χ = 1.65, df = 1 (P = 0.20); I2 = 40%
1.1.2 --- 1 mo or hospital discharge
COMBAT
PAMPer
Subtotal (95% CI)
Total events
Heterogeneity: τ = 0.34; χ = 2.99, df = 1 (P = 0.08); I 2 = 67%
Test for overall effect: Z = 0.29 (P = 0.77)
8
32
40
65
230
295
6
60
66
60
271
331
28.8%
71.2%
100.0%
1.26 [0.41, 3.88]
0.57 [0.35, 0.91]
0.72 [0.35, 1.45]
Test for overall effect: Z = 0.93 (P = 0.35)
10
51
61
65
230
295
6
88
94
60
271
331
37.3%
62.7%
100.0%
1.64 [0.56, 4.82]
0.59 [0.40, 0.89]
0.87 [0.33, 2.27]
0.1 0.2 0.5 1 2 5 10
Favors pre–hospital FFP Favors standard of care
ƐƓՊ|ՊՊՍ COMMENTARY
|_;;u|ub-Ѵr-|b;m|v;u;oѴ7;uķlou;Ѵbh;Ѵ=;l-Ѵ;-m7l1_
more likely to have sustained a blunt injury. In terms of severity of 
|_;bmfuķ-v7;=bm;70|_;bmfuv;;ub|v1ou;ķ|_;$|ub-Ѵ
patients were more severely affectedunfortunately, we do not 
have the data on prehospital intubation and interventions in the first 
ƑƓ_ouv=ou|_;$|ub-Ѵĺ
mblrou|-m|7b==;u;m1;0;|;;m|_;|ub-Ѵv;l;u];vomѴoohbm]
at the control arms, both receiving standard care. These individuals 
had identical entry criteria and in theory similar management plans 
after reaching the hospital facility. However, the 24- hour mortality 
-vƐƏѷbm|_;$|ub-Ѵ-m7ƑƑѷbm;uķ_bѴ;|_;u;vr;1-
tive 28- to 30- day mortality was 10% and 33%. Such large differ-
ences must relate to differences in severity of the injury in the two 
groups, which unfortunately is not reported with sufficient details to 
-ѴѴo-7bu;1|1olr-ubvomĺv|_;v;7-|-lv|_-;0;;m1oѴѴ;1|;7ķ
the authors should be encouraged to publish data allowing direct 
comparison between the two trials, especially detailing the injury 
severity. It would also be good to see retrospective data from both 
research networks showing whether the mortality figures observed 
in the two trials are representative of their previous experience or 
|_;_-rr;m;7|ov;Ѵ;1|-lou;Ő;uőouѴ;vvŐ$őv;;u;
population.
Since both trials were randomized, one would expect the two 
arms to be comparable in every aspect except for the intervention. 
m|_;;u|ub-Ѵķ_o;;uķƓƑĺѵѷo=|_;v|-m7-u71-u;r-|b;m|v
received prehospital red cells (vs 26.1% in the FFP arm) and an aver-
-];ƓƏƏllou;1uv|-ѴѴob70;=ou;u;-1_bm]_ovrb|-Ѵĺo|_o=|_;v;
features could contribute to the higher mortality in the standard 
1-u;]uoro=|_;;uv|7ĺ
The transfer times from the scene of injury to hospital were longer 
-|ƓƏŊƓƑlbm|;v_;mr;u=oul;70_;Ѵb1or|;uŐ;uő_bѴ;omѴ
ƐѵŊƐƖlbm|;v0uo-7-l0Ѵ-m1;Ő$őĺ|1-m0;-u];7|_-|=ou
road transfers, the interval is so short that it is unlikely that any prehos-
pital intervention will make much difference, and intervention driven 
differences would be more likely seen as the transfer time increases.
Irrespective of all the above issues, we believe the two studies 
show that if there is a benefit for prehospital FFP, this is not due to 
the clotting factors in the product. The coagulopathy of the patients 
in both trials on arrival to hospital was very mild, with a median pro-
|_uol0bm|bl;u-|boou!o=ƐĺƒouѴ;vvĺu|_;ulou;|_;$
trial investigators report that the median levels for fibrinogen and 
factors II, V, VII, IX, XI, and XIII on arrival to hospital were normal in 
both groups and indeed were higher in the non- FFP group.
o-7;uv;;;m|v bm u;Ѵ-|bom|o|_;-7lbmbv|u-|bomo= |_;
were observed but three important issues need to be considered 
before implementing prehospital FFP as a policy: 
Őő$_;v;7-v-mo|bu-ѴѴbm-1|b-|;70Ѵoo7ruo71|-m71-m
in theory transmit infections. This can be due to the donors being 
viremic shortly after infection (before the development of anti-
bodies), due to currently unknown infections, or due to prions.
(B)  The delay in getting the injured individual to hospital whist try-
ing to thaw and administer the FFP outside a clinical trial setting.
(C)  The fact that if all emergency ambulances and helicopters carry 
|_-;7 mb;uv-Ѵ 7omou 0Ѵoo7 ]uor  rѴ-vl-ķ |_; -Ѵu;-7
known frequent shortages of this product will be exacerbated. 
or_bѴb;7l-o;u1ol;|_bvѴblb|-|bombm|_;=|u;0|b|
is not currently routinely available.7
Our conclusion reflecting on these two randomized clinical trials is 
that the case for universal use of prehospital FFP is not yet made. Until 
further results from these trials are published to guide interpretation 
of current evidence and planning of future large pragmatic trials, it 
would be better for first response teams to concentrate on getting 
the injured individual to the controlled hospital environment as soon 
as possible, rather than investing precious time in administering FFP 
before transfer. Indeed, even assuming plasma can benefit a subgroup 
of more severely injured patients, it might be difficult to stratify them 
with the little time and few tools available at the injury site.
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